Publications - SFB 1479

Selected publications of the first funding period at a glance.

PIs of CRC1479 are first or last author and CRC1479 funding is indicated in the acknowledgement

Vinnakota JM et al. Nature Cancer 2024 doi: 10.1038/s43018-024-00764-7

Schmitt M et al. Nature 2022 doi: 10.1038/s41586-022-05426-1

Masuda T et al. Nature 2022 doi: 10.1038/s41586-022-04596-2

Friedrich M et al. Nature Cancer 2022 doi: 10.1038/s43018-021-00201-z

Sankowski R et al. Nature Medicine 2024 doi: 10.1038/s41591-023-02673-1

Wertheimer T et al. Nature Immunol. 2024 doi: 10.1038/s41590-024-01755-7

Maas-Bauer K et al. Nature Commun. 2024 doi: 10.1038/s41467-024-44703-7

Velasco Cárdenas RM et al. Nature Immunol. 2023 doi: 10.1038/s41590-023-01658

Zhang YW et al. Nature Cell Biology 2022 doi: 10.1038/s41556-022-00931-x

Ho J et al. Blood 2022 doi: 10.1182/blood.2022016082

Rückert T et al. Sci Transl Med. 2022 doi: 10.1126/scitranslmed.abp9675.

Talvard-Balland N et al. J Clin Invest. 2024 doi: 10.1172/JCI177460.

Denk D et al. Immunity 2022 doi: 10.1016/j.immuni.2022.09.014

Schmidt D et al. Cancer Res. 2024 doi: 10.1158/0008-5472.CAN-23-3553

Nicolas AM et al. Cancer Cell. 2022 doi: 10.1016/j.ccell.2022.01.004

Grünwald BT et al. Cell 2021 doi: 10.1016/j.cell.2021.09.022.

Vinnakota JM et al. Sci Transl Med. 2024 doi: 10.1126/scitranslmed.adj9672.

Edwards-Hicks J et al. Nature Immunol. 2023 doi: 10.1038/s41590-023-01419.

Saller BS et al. Immunity 2024 doi: 10.1016/j.immuni.2024.10.012.

Heim K et al. Nature Immunol. 2024 doi: 10.1038/s41590-024-01928-4.

Gallage S et al. Cell Metab. 2024 doi: 10.1016/j.cmet.2024.04.015.

Zhang Z et al. Nature Immunol. 2025 doi: 10.1038/s41590-024-02027-0.

Braun L et al. Cancer Cell. 2025 doi: 10.1016/j.ccell.2025.01.004.

Denk D et al. Immunity 2025 doi: 10.1016/j.immuni.2025.02.005

Gorantla SP et al. Nature Commun 2025 doi: 10.1038/s41467-025-60019-6

Scherer N. et al. Nature Genet. 2025 doi: 10.1038/s41588-024-01965-7

Chatterjee S et al. J Exp Med 2025 doi: 10.1084/jem.20242180

Ardura-Fabregat A et al. Nature Neurosci. 2025 doi: 10.1038/s41593-025-02006-0.

Leiloti et al. Nature Cell Biology 2025 doi: 10.1038/s41556-025-01709-7

Publications based on CRC1479 funding

Lalioti ME, Romero-Mulero MC, Karabacz N, Mess J, Demollin H, Rettkowski J, Schuldes K, Mitterer M, Wadle C, Shoumariyeh K, Egg M, Alfonso-Gonzalez C, Jäcklein K, Schönberger K, Karantzelis N, Reisig G, Aktories P, Mayer IM, Tsoukala I, Schäffer A, Tirado-Gonzalez I, Dugourd A, Braun LM, Silva-Rego B, Jones MJ, Kierdorf K, Saez-Rodriguez J, Reising K, Walter SG, Medyouf H, Hilgers V, Ghiaur G, Zeiser R, Karpova D, Renders S, Gravius S, Buescher J, Cabezas-Wallscheid N. Differentiation, ageing and leukaemia alter the metabolic profile of human bone marrow haematopoietic stem and progenitor cells. Nat Cell Biol. 2025 Jul 15. doi: 10.1038/s41556-025-01709-7. Epub ahead of print.

Ardura-Fabregat A, Bosch LFP, Wogram E, Mossad O, Sankowski R, Aktories P, Kieger L, Cook J, Hasavci D, Ulupinar H, Brock D, Wang F, Iovino N, Wald S, Preissl S, Yilmaz B, Schnepf D, Macpherson AJ, Blank T, Kierdorf K, Prinz M. Response of spatially defined microglia states with distinct chromatin accessibility in a mouse model of Alzheimer’s disease. Nat Neurosci. 2025 Jul 14. doi: 10.1038/s41593-025-02006-0. Epub ahead of print.

Chatterjee S, Rückert T, Martin I, Michaeli E, Buescher J, Apostolova P, Erny D, Lalioti ME, Biavasco F, Hartmann A, Runge S, Braun LM, Talvard-Balland N, Adams RC, Schmitt-Graeff A, Cook J, Wenger V, Athanassopoulos D, Hasavci D, Vallejo-Janeta AP, Blank T, Schaible P, Vinnakota JM, Zähringer A, Ganal-Vonarburg SC, Melchinger W, Pfeifer D, Köhler N, Rosshart SP, Michonneau D, Socié G, Andrieux G, Cabezas-Wallscheid N, Boerries M, Prinz M, Zeiser R. Gut microbiota-derived TMAVA is a modulator of acute CNS-GVHD. J Exp Med. 2025 Sep 1;222(9):e20242180. doi: 10.1084/jem.20242180. Epub 2025 Jul 8.

Peighambari A, Huang H, Metzger P, Adlesic M, Zodel K, Schäfer S, Seidel P, Braun LM, Hülsdünker J, Melchinger W, Follo M, Ku M, Haug S, Li Y, Köttgen A, Schell C, von Elverfeldt D, Reichardt W, Zeiser R, Heikenwalder M, Höfflin R, Börries M, Frew IJ. Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance. Sci Rep. 2025 Jun 5;15(1):19818. doi: 10.1038/s41598-025-04917-1.

Gorantla SP, Rassner M, Crossley KA, Müller TA, Poggio T, Khaja Saleem S, Kleinfelder H, Gambheer SMM, Endres C, Schaberg S, Schmidt D, Prince G, Gonzalez-Menendez I, Bentrop D, Trittler R, Rylova S, Pfeifer D, Andrieux G, Quintanilla-Martinez L, Illert AL, von Bubnoff N, Zeiser R, Duyster J. Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling. Nat Commun. 2025 May 24;16(1):4833. doi: 10.1038/s41467-025-60019-6.

Ho NHJG, Talvard-Balland N, Köhler N, Zeiser R. Immune Escape of Acute Myeloid Leukemia after Transplantation. Blood Cancer Discov. 2025 May 5;6(3):168-181. doi: 10.1158/2643-3230.BCD-24-0063.

Zähringer A, Morgado I, Erny D, Ingelfinger F, Gawron J, Chatterjee S, Wenger V, Schmidt D, Schwöbel LF, Adams RC, Langenbach M, Hartmann A, Osswald N, Wolf J, Schlunck G, Briquez PS, Grueter K, Ruess DA, Frew I, Burk AC, Holzmüller V, Grimbacher B, Michonneau D, Andrieux G, Socié G, Kolter J, Börries M, Follo M, Blaeschke F, Sevenich L, Prinz M, Zeiser R, Vinnakota JM. AhR activation mitigates graft-versus-host disease of the central nervous system by reducing microglial NF-κB signaling. Blood Adv. 2025 Mar 31:bloodadvances.2024015000. doi: 10.1182/bloodadvances.2024015000. Epub ahead of print.

Denk D, Ramakrishnan M, Conche C, Pallangyo C, Pesic M, Ceteci F, Kennel KB, Kirisözü AC, Engel E, Mohs K, Ritter B, Pardo AM, Özkurt E, Hildebrand F, Waisman A, Arkan MC, Greten FR. IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis. Immunity. 2025 Mar 11;58(3):701-715.e8. doi: 10.1016/j.immuni.2025.02.005. Epub 2025 Feb 28.

Rodov A, Baniadam H, Zeiser R, Amit I, Yosef N, Wertheimer T, Ingelfinger F. Towards the Next Generation of Data-Driven Therapeutics Using Spatially Resolved Single-Cell Technologies and Generative AI. Eur J Immunol. 2025 Feb;55(2):e202451234. doi: 10.1002/eji.202451234.

Müller M, Zodel K, Abhari BA, Cuomo F, Nizamuddin S, Metzger P, Boerries M, Timmers HTM, Frew IJ. KDM5C and KDM5D mutations have different consequences in clear cell renal cell carcinoma cells. Commun Biol. 2025 Feb 15;8(1):244. doi: 10.1038/s42003-025-07695-8.

Braun LM, Giesler S, Andrieux G, Riemer R, Talvard-Balland N, Duquesne S, Rückert T, Unger S, Kreutmair S, Zwick M, Follo M, Hartmann A, Osswald N, Melchinger W, Chapman S, Hutchinson JA, Haferkamp S, Torster L, Kött J, Gebhardt C, Hellwig D, Karantzelis N, Wallrabenstein T, Lowinus T, Yücel M, Brehm N, Rawluk J, Pfeifer D, Bronsert P, Rogg M, Mattern S, Heikenwälder M, Fusco S, Malek NP, Singer S, Schmitt-Graeff A, Ceteci F, Greten FR, Blazar BR, Boerries M, Köhler N, Duyster J, Ihorst G, Lassmann S, Keye P, Minguet S, Schadendorf D, Ugurel S, Rafei-Shamsabadi D, Thimme R, Hasselblatt P, Bengsch B, Schell C, Pearce EL, Meiss F, Becher B, Funke-Lorenz C, Placke JM, Apostolova P, Zeiser R. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell. 2025 Feb 10;43(2):269-291.e19. doi: 10.1016/j.ccell.2025.01.004.

Scherer N, Fässler D, Borisov O, Cheng Y, Schlosser P, Wuttke M, Haug S, Li Y, Telkämper F, Patil S, Meiselbach H, Wong C, Berger U, Sekula P, Hoppmann A, Schultheiss UT, Mozaffari S, Xi Y, Graham R, Schmidts M, Köttgen M, Oefner PJ, Knauf F, Eckardt KU, Grünert SC, Estrada K, Thiele I, Hertel J, Köttgen A. Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet. 2025 Jan;57(1):193-205. doi: 10.1038/s41588-024-01965-7. Epub 2025 Jan 2.

Catalano A, Haas LS, Zodel K, Adlesic M, Cuomo F, Peighambari A, Metzger P, Huang H, Haug S, Köttgen A, Köhler N, Boerries M, Frew IJ. Mutations in tumor suppressor genes Vhl and Rassf1a cause DNA damage, chromosomal instability and induce gene expression changes characteristic of clear cell renal cell carcinoma. Kidney Int. 2024 Dec 24:S0085-2538(24)00912-8. doi: 10.1016/j.kint.2024.12.003. Epub ahead of print.

Zhang Z, Langenbach M, Sagar S, Fetsch V, Stritzker J, Severa E, Meng K, Winkler F, Rana N, Zoldan K, Godbole I, Solis S, Weber JS, Rafei-Shamsabadi D, Lehr S, Diehl R, Venhoff AC, Voll RE, Buettner N, Neumann-Haefelin C, Boettler T, Hofmann M, Boerries M, Meiss F, Zeiser R, Thimme R, Herati RS, Bengsch B. Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1⁺CD8⁺ T cells. Nat Immunol. 2024 Dec 19. doi: 10.1038/s41590-024-02027-0. Epub ahead of print.

D’Avanzo C, Blaeschke F, Lysandrou M, Ingelfinger F, Zeiser R. Advances in cell therapy: progress and challenges in hematological and solid tumors. Trends Pharmacol Sci. 2024 Dec;45(12):1119-1134. doi: 10.1016/j.tips.2024.10.016. Epub 2024 Nov 27.

Saller BS, Wöhrle S, Fischer L, Dufossez C, Ingerl IL, Kessler S, Mateo-Tortola M, Gorka O, Lange F, Cheng Y, Neuwirt E, Marada A, Koentges C, Urban C, Aktories P, Reuther P, Giese S, Kirschnek S, Mayer C, Pilic J, Falquez-Medina H, Oelgeklaus A, Deepagan VG, Shojaee F, Zimmermann JA, Weber D, Tai YH, Crois A, Ciminski K, Peyronnet R, Brandenburg KS, Wu G, Baumeister R, Heimbucher T, Rizzi M, Riedel D, Helmstädter M, Buescher J, Neumann K, Misgeld T, Kerschensteiner M, Walentek P, Kreutz C, Maurer U, Rambold AS, Vince JE, Edlich F, Malli R, Häcker G, Kierdorf K, Meisinger C, Köttgen A, Jakobs S, Weber ANR, Schwemmle M, Groß CJ, Groß O. Acute suppression of mitochondrial ATP production prevents apoptosis and provides an essential signal for NLRP3 inflammasome activation. Immunity. 2024 Nov 15:S1074-7613(24)00492-8. doi: 10.1016/j.immuni.2024.10.012. Epub ahead of print.

Giesler S, Riemer R, Lowinus T, Zeiser R. Immune-mediated colitis after immune checkpoint inhibitor therapy. Trends Mol Med. 2024 Oct 29:S1471-4914(24)00266-1. doi: 10.1016/j.molmed.2024.09.009. Epub ahead of print.

Heim K, Sagar, Sogukpinar Ö, Llewellyn-Lacey S, Price DA, Emmerich F, Kraft ARM, Cornberg M, Kielbassa S, Knolle P, Wohlleber D, Bengsch B, Boettler T, Neumann-Haefelin C, Thimme R, Hofmann M. Attenuated effector T cells are linked to control of chronic HBV infection. Nat Immunol. 2024 Sep;25(9):1650-1662. doi: 10.1038/s41590-024-01928-4. Epub 2024 Aug 28. PMID: 39198634.

Zeiser R. Introduction to a review series on oncogenic signaling and immune evasion in hematologic malignancies. Blood. 2024 Jun 27;143(26):2679. doi: 10.1182/blood.2024023825.

Talvard-Balland N, Braun LM, Dixon KO, Zwick M, Engel H, Hartmann A, Duquesne S, Penter L, Andrieux G, Rindlisbacher LS, Acerbis A, Ehmann J, Köllerer C, Ansuinelli M, Rettig A, Moschallski K, Apostolova P, Brummer T, Illert AL, Schramm MA, Cheng Y, Köttgen A, Duyster J, Menssen HD, Ritz J, Blazar BR, Boerries M, Schmitt Graeff A, Sariipek N, van Galen P, Buescher JM, Cabezas-Wallscheid N, Pahl HL, Pearce EL, Soiffer RJ, Wu CJ, Vago L, Becher B, Köhler N, Wertheimer T, Kuchroo VK, Zeiser R. Oncogene induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice. J Clin Invest. 2024 Jun 25:e177460. doi: 10.1172/JCI177460. Epub ahead of print.

Publications based on CRC1479 funding

Contact